Prellis Biologics and start-up Volumetric Bio plan to commercialise their bioprinting projects. San Francisco-based Prellis, which raised $8.7m in funding in Late last month, aims to market its 3D-printed vascular scaffolds, as well as vascularised skin grafts and a vascular shunt for dialysis patients made from their own tissue. Meanwhile, Volumetric was launched to commercialise the bioprinters, materials and reagents supporting research into vascular networks.
Prellis Biologics and start-up Volumetric Bio plan to commercialise their bioprinting projects. San Francisco-based Prellis, which raised $8.7m in funding in July, aims to market its 3D-printed vascular scaffolds, as well as vascularised skin grafts and a vascular shunt for dialysis patients made from their own tissue. Meanwhile, Volumetric was launched to commercialise the bioprinters, materials and reagents supporting research into vascular networks.